Research study Program year 2025 Source: CMS Open Payments

Targeted Agent and Profiling Utilization Registry Tapur Study

Research payments

$26,166,021

167 payments

Through program year 2025, $26,166,021 in research payments was reported against Targeted Agent and Profiling Utilization Registry Tapur Study, across 167 payments, paid by Pfizer Inc..

Paid by: Pfizer Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$809,769	6
2024	Research	$967,592	11
2023	Research	$3,470,903	24
2022	Research	$3,617,017	23
2021	Research	$2,505,565	22
2020	Research	$5,371,611	34
2019	Research	$9,423,565	47

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $26,166,021 167 payments

Who received the money Research payments · program years 2019–2025

Biomatrix Specialty Pharmacy Of MD Organisation paid for research $14,696,827 92 payments
American Society Of Clinical Oncology INC Organisation paid for research $8,075,028 57 payments
Biomatrix Specialty Pharmacy Organisation paid for research $1,334,416 8 payments
Cardinal Health Specialty Pharmacy Organisation paid for research $1,278,996 8 payments
Biomatrix Specialty Pharm Of MD Organisation paid for research $780,753 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

2 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.